الصفحة الرئيسية>>Signaling Pathways>> Others>>SEC inhibitor KL-1

SEC inhibitor KL-1 (Synonyms: KL-1)

رقم الكتالوجGC38063

مثبط SEC KL-1 (KL-1) ، مركب الرصاص المحاكي للببتيد ، هو مثبط قوي وانتقائي للاستطالة الفائقة (SEC) ويعطل التفاعل بين بروتين السقالات SEC AFF4 و P-TEFb ، مما يؤدي إلى ضعف إطلاق Pol II من مواقع التوقف القريبة للمروج وانخفاض متوسط معدل استطالة النسخيُظهر مثبط SEC KL-1 تأثيرًا مثبطًا يعتمد على الجرعة على تفاعل AFF4-CCNT1 مع Ki البالغ 3.48 ميكرومتر

Products are for research use only. Not for human use. We do not sell to patients.

SEC inhibitor KL-1 التركيب الكيميائي

Cas No.: 900308-84-1

الحجم السعر المخزون الكميّة
1mg
51٫00
متوفر
5mg
153٫00
متوفر
10mg
243٫00
متوفر
25mg
364٫00
متوفر
50mg
765٫00
متوفر
100mg
882٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SEC inhibitor KL-1 (KL-1), a peptidomimetic lead compound, is a potent, selective super elongation complex (SEC) inhibitor and disrupts the interaction between the SEC scaffolding protein AFF4 and P-TEFb, resulting in impaired release of Pol II from promoter-proximal pause sites and a reduced average rate of processive transcription elongation. SEC inhibitor KL-1 exhibits an dose-dependent inhibitory effect on AFF4-CCNT1 interaction with a Ki of 3.48 μM[1].

[1]. Liang K, et al. Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced CancerTherapy. Cell. 2018 Oct 18;175(3):766-779.

مراجعات

Review for SEC inhibitor KL-1

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SEC inhibitor KL-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.